Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023

Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023

Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022

Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference

Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors